Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$43.00 USD

43.00
240,438

-0.39 (-0.90%)

Updated Nov 29, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More

by Zacks Equity Research

GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

by Zacks Equity Research

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.

CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine

by Zacks Equity Research

If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.

CDC Narrows Age Recommendation for Use of RSV Vaccine

by Zacks Equity Research

The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.

Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

by Zacks Equity Research

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.

Kinjel Shah headshot

Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?

by Kinjel Shah

While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Moderna (MRNA) closed at $137.60 in the latest trading session, marking a +0.44% move from the prior day.

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

by Zacks Equity Research

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for QQEW

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News

by Zacks Equity Research

Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $148.59, marking a -1.6% move from the previous day.

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

by Zacks Equity Research

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

by Zacks Equity Research

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

5 Stocks Propelling S&P 500 to 25th Record High

by Sweta Killa

The S&P 500 touches a record high for the 25th time this year, powered by technology stocks. We have highlighted five technology stocks, HPE, MRNA, AVGO, MU and LRCX, leading the way higher in the latest trading session.

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Sundeep Ganoria headshot

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

by Sundeep Ganoria

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.